Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Affymetrix and ScreenCell Announce Worldwide Distribution Agreement

Published: Friday, May 18, 2012
Last Updated: Friday, May 18, 2012
Bookmark and Share
Affymetrix releases first circulating tumour cell platform technology for 4-color RNA-ISH.

Combination of ScreenCell's isolation devices and Affymetrix' QuantiGene(R) ViewRNA ISH technology enables easy, accessible, sensitive, multiplex, low-cost system to enumerate and characterize CTCs and other rare cells.

Affymetrix, Inc. and ScreenCell announced the signing of a worldwide distribution agreement for ScreenCell's isolation devices and dilution buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

The agreement makes Affymetrix the exclusive distributor of ScreenCell(R) products* used in combination with in situ hybridization (ISH) assays, microarray assays, and other non-PCR based nucleic acid assays including Affymetrix' industry-leading QuantiGene(R) ViewRNA Assays,* QuantiGene(R) Plex Assays,* and GeneChip(R) Microarray Assays.* The QuantiGene(R) ViewRNA CTC platform, consist of ScreenCell's products and Affymetrix' QuantiGene ViewRNA Assays, is now available from Affymetrix.

"This agreement is a powerful combination of two innovative technologies, one designed to isolate rare cells of potentially significant prognostic and predictive value in cancer, and another, our QuantiGene ViewRNA ISH Cell Assays, designed to detect single RNA transcripts in single CTCs and rare cells with high specificity," stated George Bers, Vice President & General Manager, Expression Business Unit -- Panomics for Affymetrix. "Today we are launching our CTC platform, which combines our highly sensitive and specific QuantiGene ViewRNA Assay with ScreenCell's isolation devices. We believe this platform may potentially have a dramatic impact on disease detection, enabling researchers in translational sciences to further examine the impact on treatment, management and outcome in cancer. We are proud to be ScreenCell's global partner and look forward to releasing additional assays and research applications."

ScreenCell offers innovative, single-use devices to isolate by size and characterize a wide variety of tumor cells, both live and fixed, including mesenchymal cells, cancer stem cells, microembolii and cancer cells of non-epithelial origin. These cells, which are considered to be important in metastasis, are often not captured or cannot be sensitively detected through existing technologies that only target cells expressing EpCam, a transmembrane glycoprotein on epithelial cells. With the ScreenCell devices, collected cells are also well preserved morphologically and can be isolated and grown in culture for drug screening or further genomics analysis.

"Our goal in designing ScreenCell(R) technologies was to create a universal system, not limited to detection of cells of non-epithelial origin and free of any bias potentially linked to the use of antibodies for cell capture," stated David Znaty, Chief Executive Officer of ScreenCell. "Our goal is to provide a technology to support further research for use in personalized medicine by creating a broadly accessible, non-invasive evaluation of specific, potential therapeutic targets. We are excited to work with Affymetrix not just for their commercial strength, but because we believe strongly in our combined technologies."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Affymetrix, BioRealm, RUCDR Ally
Affymetrix, BioRealm, and RUCDR Infinite Biologics today announced a strategic alliance to genotype the National Institute of Drug Abuse biorepository.
Wednesday, July 08, 2015
Affymetrix Acquires Assets of Eureka Genomics
Aquisition will enable provision of high throughput and economical crop and animal genotyping.
Thursday, May 14, 2015
CollabRx, Affymetrix To Develop Analytical Tools For Integrated Clinical Cancer Panels
The overall objective of the partnership is to provide scientific knowledge for biomarker CNV profiles in cancer.
Wednesday, April 16, 2014
University of Bristol Collaborates with Affymetrix on Genotyping Arrays
Results from the array presented at the 2014 Plant and Animal Genome conference.
Wednesday, January 15, 2014
Affymetrix Reports 2013 First Quarter Results
Affymetrix, Inc. reported its operating results for the three months ended March 31, 2013.
Wednesday, May 01, 2013
Affymetrix and BioDiscovery Announce Software for Analysis of Whole Genome Copy Number Data
Generated from FFPE solid tumor samples for accelerating cancer translational research.
Thursday, April 11, 2013
Ingenuity Systems and Affymetrix Partner
Companies collaborate to eliminate microarray expression analysis bottleneck.
Monday, April 08, 2013
Affymetrix Announces Collaboration with Centre for Proteomic and Genomic Research (CPGR)
CPGR will provide gene expression and Axiom genotyping services to African researchers using GeneTitan® Multi-Channel (MC) Instrument.
Tuesday, November 20, 2012
Affymetrix and Singapore-based Start-up PathGEN Dx Sign Partnership
Agreement for diagnostic test development for pathogen detection.
Monday, August 27, 2012
Affymetrix Completes Acquisition of eBioscience Holding Company, Inc.
Acquisition expands Affymetrix’s addressable markets by more than $2.5 billion per year.
Thursday, June 28, 2012
Affymetrix Announces Proposed $105 Million Offering of Convertible Senior Notes Due 2019
Company expects to grant an option to purchase up to $10 million aggregate principal amount of additional notes.
Thursday, June 21, 2012
Affymetrix Announces Research Collaboration with MGH
Collaboration and licensing agreement to validate and develop new oncology biomarker tests.
Thursday, June 07, 2012
Affymetrix and Leica Microsystems Announce Worldwide Collaboration
The collaboration automates Affymetrix’ QuantiGene® ViewRNA ISH Tissue Assay on the Leica BOND RX staining platform for research applications.
Thursday, May 31, 2012
Affymetrix and ScreenCell Announce Worldwide Distribution Agreement for CTC Technology
Combination of ScreenCell’s isolation devices and Affymetrix’ QuantiGene® ViewRNA ISH technology enables easy, accessible, sensitive, multiplex, low-cost system to enumerate and characterize CTCs and other rare cells.
Friday, May 18, 2012
Affymetrix and BGI Enter Strategic Collaboration
Partnership to co-develop and commercialize genomic microarrays for the agricultural community.
Friday, January 13, 2012
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!